Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026

HomeCompaniesSectorsCalendarLast night
Screens
WarningsPrice and conditionThen and nowSize bandsCeased filers
Tools
Time machinePoint in timeData exportsRun logForecast logEDGAR company search
Method
MethodCoverageAbout
Entera Bio Ltd.ENTX · healthcare
GradeSlothDfourth fifth of 371 graded peers; percentile 65.4, sampling error 2.5 points; lower is stronger
Rank243 of 371
ProfitabilityCpercentile 54.8
SolvencyCpercentile 49.8
Growth and financingCpercentile 54.8
Reliability0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$12.5M to $120M assetstotal assets $16.0M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsdegenerate inputsnot computable: distress, fortress balance sheet
Inputs computable7 of 14
Graded fromfilings received through Mar 27, 2026196 days before the rescan; every figure keyed to the SEC receipt date
Last close$2.512026-10-08; market equity $434.6M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$2$4NovDecJanFebMarAprMayJunJulAugSepOctED$2.50
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Mar 21, 2022nonen/aQ2
Mar 21, 2024nonen/aQ1
Apr 21, 2025E86.8Q1
Apr 21, 2026D68.3Q2

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 27, 2026; the document on sec.gov.

Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. We concentrate on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm. Our pipeline includes differentiated, first-in-class oral peptides targeting PTH(1-34), GLP-1/Glucagon and GLP-2: Currently, most protein therapies are administered via frequent intravenous, subcutaneous or intramuscular injections.

Warnings [top]

Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 54.8
Gross profitability0.0%[1,3]32.2%95.83722025-12-31
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(32.1%)[1,4-6](6.6%)13.78112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
annual revenue must exceed $100,000
Solvency, sleeve percentile 49.8
Twelve-month failure probabilitynot computable0.07%
latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime(20.27)[1,7-12](0.31)73.87562025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
one or more required annual facts are missing
Current ratio6.94x[7-8]2.96x25.98392025-12-31
Growth and financing, sleeve percentile 54.8
Revenue growth, three-year compound(32.1%)[2,13-15]10.0%91.84152025-12-31
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
NOPAT must exceed $100,000
Asset growth, three years6.8%[1,6,16-17]2.1%37.17042025-12-31
Net share issuance, one year2.6%[18-19]2.5%35.46342026-03-23

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Sleeves are equal-weighted; within a sleeve each computable input carries equal weight. Composite 0.072; sampling error 2.5 percentile points on 371 peers.

Among 371 Peers [top]

ABCDEJNJ, Johnson & Johnson; C, percentile 44.9; market equity $618.1BJNJLLY, ELI Lilly & Co.; C, percentile 55.7; market equity $1.1TLLYABBV, AbbVie Inc.; D, percentile 63.2; market equity $481.4BABBVGILD, Gilead Sciences, Inc.; D/E, percentile 78.9; market equity $182.4BGILDMRK, Merck & Co., Inc.; D/E, percentile 80.8; market equity $351.3BMRKAMGN, Amgen Inc.; E, percentile 85.1; market equity $220.3BAMGNENTX 65.4strongerweaker

Composite score of every graded peer, smoothed. Vertical rules are the letter band edges at the 20th, 40th, 60th and 80th percentiles. Small dots are the six largest peers by market equity.

RankCompanyPercentileLetterWarnings
238Integra Lifesciences Holdings Corp. (IART)

Integra Lifesciences Holdings Corp. (IART)

Dfourth fifth; percentile 64.1

Nasdaq · Surgical & Medical Instruments & Apparatus

market equity $1.0B; last close $13.43

No active warnings; 10 of 14 inputs

64.1D
239Alpha Teknova, Inc. (TKNO)

Alpha Teknova, Inc. (TKNO)

Dfourth fifth; percentile 64.3

Nasdaq · In Vitro & In Vivo Diagnostic Substances

market equity $453.1M; last close $8.45

No active warnings; 9 of 14 inputs

64.3D
240Arvinas, Inc. (ARVN)

Arvinas, Inc. (ARVN)

Dfourth fifth; percentile 64.6

Nasdaq · Pharmaceutical Preparations

market equity $491.1M; last close $7.51

Warnings: short runway, fortress balance sheet; 7 of 14 inputs

64.6Dshort runway, fortress balance sheet
241Organogenesis Holdings Inc. (ORGO)

Organogenesis Holdings Inc. (ORGO)

Dfourth fifth; percentile 64.9

Nasdaq · Pharmaceutical Preparations

market equity $164.7M; last close $1.27

Warnings: fortress balance sheet; 7 of 14 inputs

64.9Dfortress balance sheet
242Fulgent Genetics, Inc. (FLGT)

Fulgent Genetics, Inc. (FLGT)

Dfourth fifth; percentile 65.1

Nasdaq · Services-Medical Laboratories

market equity $572.9M; last close $20.87

Warnings: short runway; 8 of 14 inputs

65.1Dshort runway
243Entera Bio Ltd. (ENTX)

Entera Bio Ltd. (ENTX)

Dfourth fifth; percentile 65.4

Nasdaq · Biological Products, (No Diagnostic Substances)

market equity $432.9M; last close $2.51

Warnings: degenerate inputs; 7 of 14 inputs

65.4Ddegenerate inputs
244Dentsply Sirona Inc. (XRAY)

Dentsply Sirona Inc. (XRAY)

Dfourth fifth; percentile 65.7

Nasdaq · Dental Equipment & Supplies

market equity $1.7B; last close $8.68

No active warnings; 9 of 14 inputs

65.7D
245InspireMD, Inc. (NSPR)

InspireMD, Inc. (NSPR)

Dfourth fifth; percentile 65.9

Nasdaq · Surgical & Medical Instruments & Apparatus

market equity $22.3M; last close $0.47

Warnings: dilution, short runway, distress; 9 of 14 inputs

65.9Ddilution, short runway, distress
246Angiodynamics Inc. (ANGO)

Angiodynamics Inc. (ANGO)

Dfourth fifth; percentile 66.2

Nasdaq · Surgical & Medical Instruments & Apparatus

market equity $472.3M; last close $11.22

Warnings: fortress balance sheet; 7 of 14 inputs

66.2Dfortress balance sheet
247AIM ImmunoTech Inc. (AIM)

AIM ImmunoTech Inc. (AIM)

Dfourth fifth; percentile 66.5

NYSE · Biological Products, (No Diagnostic Substances)

market equity $5.5M; last close $0.18

Warnings: late filer, degenerate inputs, distress; 8 of 14 inputs

66.5Dlate filer, degenerate inputs, distress
248Exagen Inc. (XGN)

Exagen Inc. (XGN)

Dfourth fifth; percentile 66.8

Nasdaq · Services-Medical Laboratories

market equity $197.9M; last close $8.15

Warnings: dilution, fortress balance sheet; 8 of 14 inputs

66.8Ddilution, fortress balance sheet
Peer policyLetterPercentilePeers
all graded filers, equal sleevesD70.12204
sector peers, equal sleeves (the grade)D65.4371
same exchange, equal sleevesD69.31219
sector peers, equal inputsD67.8371

Each letter is one fifth of the 371 graded peers, about 74 companies. A boundary letter (A/B, B/C, C/D, D/E) marks a percentile within one sampling error of a band edge.

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month53.6%8.0%78hotter than 78 of 100 peers
Distance from 52-week high(36.2%)(31.4%)41closer to its high than 41 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(1.7%)(1.0%)48pricier than 52 of 100 peers
Book value to price0.020.2814pricier than 86 of 100 peers
Sales to price0.000.311pricier than 99 of 100 peers
Composite equity issuance, five yearsnot computable20.3%a share count from five years earlier is required
Relative strength against the sector, log excess return0.22(0.14)78ahead of 78 of 100 peers

Inputs: market equity $432.9M; EBIT -$11.5M; free cash flow -$7.5M; book equity $7.3M; sales $42,000; cash $11.3M[20].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(121.8%)✗ fail[4,6]
Operating cash flow above zero-$7.4M✗ fail[5]
Return on assets improved(40.7 pts)✗ fail[4,6,16,21]
Operating cash flow exceeds net income$4.1M✓ pass[4-5]
Long-term leverage felln/a[1,6,16]
Current ratio improved(68.5 pts)✗ fail[7-8,22-23]
No new shares issued2.6%✗ fail[18-19]
Gross margin improvedn/a[2-3,13,24]
Asset turnover improved(1.1 pts)✗ fail[2,6,13,16]
Cash, filings, liquidity
Cash and equivalents$11.3M[25]
Operating cash flow, four quarters-$10.9M[5,25-29]
Months of runway12.5
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing63
10-Q received Aug 7, 2026
Median daily dollar volume$1.1M
63 sessions
Days since newest grade input196

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$16.0M2025-12-312026-03-2710-Kfiling · viewer · series
2revenueus-gaap:Revenues$42,0002025-12-312026-03-2710-Kfiling · viewer · series
3gross profitus-gaap:GrossProfit$02025-12-312026-03-2710-Kfiling · viewer · series
4net incomeus-gaap:NetIncomeLoss-$11.4M2025-12-312026-03-2710-Kfiling · viewer · series
5operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$7.4M2025-12-312026-03-2710-Kfiling · viewer · series
6assetsus-gaap:Assets$9.4M2024-12-312026-03-2710-Kfiling · viewer · series
7current assetsus-gaap:AssetsCurrent$15.3M2025-12-312026-03-2710-Kfiling · viewer · series
8current liabilitiesus-gaap:LiabilitiesCurrent$2.2M2025-12-312026-03-2710-Kfiling · viewer · series
9retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$125.4M2025-12-312026-03-2710-Kfiling · viewer · series
10operating incomeus-gaap:OperatingIncomeLoss-$11.5M2025-12-312026-03-2710-Kfiling · viewer · series
11book equityus-gaap:StockholdersEquity$13.1M2025-12-312026-03-2710-Kfiling · viewer · series
12liabilitiesus-gaap:Liabilities$2.9M2025-12-312026-03-2710-Kfiling · viewer · series
13revenueus-gaap:Revenues$181,0002024-12-312026-03-2710-Kfiling · viewer · series
14revenueus-gaap:Revenues$02023-12-312025-03-2810-Kfiling · viewer · series
15revenueus-gaap:Revenues$134,0002022-12-312024-03-0810-Kfiling · viewer · series
16assetsus-gaap:Assets$11.8M2023-12-312025-03-2810-Kfiling · viewer · series
17assetsus-gaap:Assets$13.1M2022-12-312024-03-0810-Kfiling · viewer · series
18shares outstandingdei:EntityCommonStockSharesOutstanding46,622,2392026-03-232026-03-2710-Kfiling · viewer · series
19shares outstandingdei:EntityCommonStockSharesOutstanding45,420,6762025-03-202025-03-2810-Kfiling · viewer · series
20shares outstandingdei:EntityCommonStockSharesOutstanding173,141,8312026-08-032026-08-0710-Qfiling · viewer · series
21net incomeus-gaap:NetIncomeLoss-$9.5M2024-12-312026-03-2710-Kfiling · viewer · series
22current assetsus-gaap:AssetsCurrent$9.0M2024-12-312026-03-2710-Kfiling · viewer · series
23current liabilitiesus-gaap:LiabilitiesCurrent$1.2M2024-12-312026-03-2710-Kfiling · viewer · series
24gross profitus-gaap:GrossProfit$9,0002024-12-312026-03-2710-Kfiling · viewer · series
25cashus-gaap:CashAndCashEquivalentsAtCarryingValue$11.3M2026-06-302026-08-0710-Qfiling · viewer · series
26operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$6.6M2026-06-302026-08-0710-Qfiling · viewer · series
27operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$3.1M2026-03-312026-05-0810-Qfiling · viewer · series
28operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$5.5M2025-09-302025-11-1410-Qfiling · viewer · series
29operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$3.0M2025-06-302026-08-0710-Qfiling · viewer · series

Limitations [top]

Grade boundary. Percentile 65.4 is 5.4 points from the nearest band edge; sampling error is 2.5 points.

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.

Informational and educational only. Not investment advice. SEC and market data may contain errors.

If you have any comments about this page, the methodology and every line of code that produced it are in the public repository. However, due to the limited number of personnel, we are unable to provide a direct response.

Pages
Home · Companies · Sectors · Calendar · Last night
Screens
Warnings · Price and condition · Then and now · Size bands · Ceased filers
Tools
Time machine · Point in time · Data exports · Run log · Forecast log · EDGAR company search
Method
Method · Coverage · About
Source
GitHub · ezrakruger.cc
Photographs from Wikimedia Commons

bull: Raphael Schön from Vienna, Austria, CC BY 2.0; bear: U. S. Fish and Wildlife Service - Northeast Region, Public domain; elk: Oregon Department of Fish & Wildlife, Public domain; tortoise: NPS, Public domain; sloth: Charles J. Sharp, CC BY-SA 3.0; fox: Cp9asngf, CC BY-SA 4.0; sector-business_equipment: Sangitiana Fararano, CC BY-SA 2.0; sector-healthcare: User:Squidonius, myself, and User:Beliason (assumed)., CC BY-SA 4.0; sector-manufacturing: unknown, CC BY-SA 2.0; sector-shops: Wilfredor, CC BY-SA 4.0; sector-consumer_nondurables: Nielsoncaetanosalmeron, CC BY 4.0; sector-utilities: Lijovklm, CC BY-SA 4.0; sector-consumer_durables: Stilfehler, CC BY-SA 4.0; sector-chemicals: PEO ACWA, CC BY 2.0; sector-energy: Arne Hückelheim, CC BY-SA 3.0; sector-telecom: Wikideas1, CC0; sector-other: Downtowngal, CC BY-SA 4.0.

Updated Oct 9, 2026